Corcept Therapeutics Inc. Stock
Heavy losses for Corcept Therapeutics Inc. today as the stock fell by -€1.410 (-6.030%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 35 € there is a hugely positive potential of 53.51% for Corcept Therapeutics Inc. compared to the current price of 22.8 €.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -6.030% | 6.942% | -3.635% | 8.571% | -24.000% | 22.581% | - |
| Gritstone Oncology Inc | 13.680% | 16.156% | -19.102% | -60.022% | -52.018% | -88.090% | - |
| Avid Bioservices Inc | 0.700% | 5.109% | 24.138% | -55.556% | 18.033% | -60.000% | 78.174% |
| Pacira Pharmaceuticals | 3.310% | 4.167% | -3.101% | -39.614% | -16.107% | -50.000% | -41.038% |
Comments
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $42.00 to $44.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat